[Glycosphingolipids as tumor markers]. 1997

L Lenícková, and F Smíd
I. interní klinika 1, LF UK a VFN, Praha.

Interest in research in the sphere of tumours has concentrated for many years on finding tumour specific antigenic structures which can be used in immunodiagnosis and immunotherapy. During the last 30 years a number of monoclonal antibodies against tumours was prepared by means of which evidence was provided that antigens associated with tumourous processes have very often the nature of carbohydrates, in particular those linked to lipids, i.e. glycolipids. Carbohydrate structures with which anti-tumour antibodies react are usually found (at least in small concentrations) also in normal tissues. In the strict sense, from the chemical aspect specific tumour antigens do not exist but rather antigens associated with the tumourous process-tumour markers. Factors which influence the presence of a glycolipid of a tumour marker may be a) a simplification of the glycolipid spectrum by incomplete biosynthesis with concurrent deficiency of higher complex glycolipids and cumulation of the glycolipid precursor, b) activation of new pathways of biosynthesis, c) changes in the ceramide portion, d) lactonisation in the carbohydrate portion of the molecule, e) changes in the accessibility of the glycolipid molecule, their conformation and density on the cell surface. The author reviews the main glycolipid tumour markers which can be used in immunodiagnostics.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006028 Glycosphingolipids Lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide (CERAMIDES). They are subdivided into NEUTRAL GLYCOSPHINGOLIPIDS comprising monoglycosyl- and oligoglycosylsphingoids and monoglycosyl- and oligoglycosylceramides; and ACIDIC GLYCOSPHINGOLIPIDS which comprises sialosylglycosylsphingolipids (GANGLIOSIDES); SULFOGLYCOSPHINGOLIPIDS (formerly known as sulfatides), glycuronoglycosphingolipids, and phospho- and phosphonoglycosphingolipids. (From IUPAC's webpage) Asialoganglioside,Asialogangliosides,Glycosphingolipid,Sphingoglycolipid,Sphingoglycolipids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

L Lenícková, and F Smíd
August 1983, Journal of the National Cancer Institute,
L Lenícková, and F Smíd
June 2021, International journal of molecular sciences,
L Lenícková, and F Smíd
August 1997, Neurochemical research,
L Lenícková, and F Smíd
January 1983, Cancer detection and prevention,
L Lenícková, and F Smíd
January 1981, Critical reviews in clinical laboratory sciences,
L Lenícková, and F Smíd
September 1982, Clinics in laboratory medicine,
L Lenícková, and F Smíd
August 2004, Seminars in cell & developmental biology,
L Lenícková, and F Smíd
March 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
L Lenícková, and F Smíd
January 1985, Progress in clinical and biological research,
L Lenícková, and F Smíd
February 1990, Der Internist,
Copied contents to your clipboard!